Last checked at 30 Jan 2018 07:00
BEXIMCO PHARMACEUTICALS LTD.
30 January 2018
Half Year Results 2017-18
Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP, LEI No 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its un-audited financial results for the six months ended 31 December 2017.
Financial highlights
Half year financial highlights
· Net sales increased 13.2% to Bangladesh Taka ("BDT") 8,638.5m / £77.3m (2016-17: BDT 7,630.6m / £79.7m)
o Domestic sales increased 12.8% to BDT 8,058.4m / £72.1m (2016-17: 7,142.0 / £74.6m)
o Export sales increased 18.7% to BDT 580.1m / £5.2m (2016-17: BDT 488.6m / £5.1m)
· Profit after tax increased 18.4% to BDT 1,317.4m / £11.8m (2016-17: BDT 1,112.9m/ £11.6m)
Second quarter financial highlights
· Net sales increased 12.8% to BDT 4,359.9m / £39.0m (2016-17: BDT 3,865.0m / £40.4m)
· Profit after tax increased 12.5% to BDT 672.9m / £6.0m (2016-17: BDT 598.0m / £6.2m)
Operational highlights
· A total of nine new products launched in the domestic market
o Three launched for the first time in Bangladesh
§ Tuspel syrup and Dextrim syrup - two combination medicines used to treat cough, stuffy nose, sinus congestion and chest congestion caused by allergies, the common cold or influenza
§ Tezolin tablet - for the treatment of acute bacterial skin and skin structure infections
· 41 registrations in 16 countries for 32 products
· Entered three new countries (Canada, Uzbekistan, Zambia)
· In the US:
o Commenced export of second product, Sotalol, a drug used to treat abnormal heart rhythms
o Received US Food and Drug Administration (FDA) approval for fourth product, muscle relaxant Methocarbamol
· Entered into a non-binding memorandum of understanding to acquire a majority shareholding (85.23%) in Nuvista Pharma, a leading pharma company in Bangladesh specialising in hormones and steroid drugs
o Post period end, entered into Share Purchase Agreements, which are due to complete by 28 February
· Received WHO Prequalification for the Company's oral solid dosage facility at Tongi
· Won the prestigious Scrip Award in the category of 'Best Company in an Emerging Market'
o First time a Bangladeshi company has won this award
Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, commented:
"During the half year, we delivered strong results, maintaining excellent sales growth across our domestic and export markets. We continued to expand our portfolio with nine new product launches in the domestic market, whilst successfully shipping our second product to the US market and receiving our fourth product approval from the US FDA.
"Importantly, our oral solid dosage facility was granted WHO Prequalification, a prerequisite to participate in tenders funded by global donor agencies for certain groups of medicines. We also undertook the first acquisition in Beximco Pharma's history, expanding and complementing our existing portfolio, which is due to complete next month. We look forward to continuing to maintain this strong financial and operational growth momentum."
The half yearly accounts can be viewed at the Company's website: www.beximcopharma.com
(Exchange rates of £1 = Taka 111.7442 for 31 December 2017 numbers and £1 = Taka 95.7228for 31 December 2016 have been used in this announcement.)
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel: +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
Northland Capital Partners Limited (Broker)
Tom Price
Tel: +44 (0)20 3861 6625
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,800 employees of the Company.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia and North America, including the USA and Canada.
Beximco Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at 31 December 2017
|
|
|
| Taka '000 |
|
| As at 31 December 2017 |
| As at 30 June 2017 |
ASSESTS |
|
|
|
|
Non-Current Assets |
| 26,719,759 |
| 24,953,317 |
Property, Plant and Equipment- Carrying Value |
| 26,174,791 |
| 24,472,468 |
Intangible Assets |
| 509,045 |
| 462,969 |
Investment in Shares |
| 35,923 |
| 17,880 |
|
|
|
|
|
Current Assets |
| 9,640,952 |
| 9,130,816 |
Inventories |
| 3,542,598 |
| 3,468,089 |
Spares & Supplies |
| 639,855 |
| 636,103 |
Accounts Receivable |
| 2,491,789 |
| 2,167,340 |
Loans, Advances and Deposits |
| 2,262,900 |
| 1,697,679 |
Short Term Investment |
| 326,550 |
| 886,577 |
Cash and Cash Equivalents |
| 377,260 |
| 275,028 |
|
|
|
|
|
TOTAL ASSETS |
| 36,360,711 |
| 34,084,133 |
|
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
|
Shareholders' Equity |
| 25,860,955 |
| 25,072,426 |
Issued Share Capital |
| 4,055,564 |
| 4,055,564 |
Share Premium |
| 5,269,475 |
| 5,269,475 |
Excess of Issue Price over Face Value of GDRs |
| 1,689,637 |
| 1,689,637 |
Capital Reserve on Merger |
| 294,951 |
| 294,951 |
Revaluation Surplus |
| 1,163,172 |
| 1,190,204 |
Unrealised Gain/(Loss) |
| 3,772 |
| 3,875 |
Retained Earnings |
| 13,384,384 |
| 12,568,720 |
|
|
|
|
|
Non-Current Liabilities |
| 6,605,295 |
| 5,605,667 |
Long Term Borrowings-Net off Current Maturity (Secured) |
| 3,559,659 |
| 2,635,907 |
Liability for Gratuity and WPPF & Welfare Funds |
| 1,176,713 |
| 1,117,094 |
Deferred Tax Liability |
| 1,868,923 |
| 1,852,666 |
|
|
|
|
|
Current Liabilities and Provisions |
| 3,894,461 |
| 3,406,040 |
Short Term Borrowings (Secured) |
| 711,954 |
| 1,239,758 |
Long Term Borrowings-Current Maturity (Secured) |
| 773,565 |
| 715,790 |
Creditors and Other Payables |
| 1,197,959 |
| 783,839 |
Accrued Expenses |
| 300,232 |
| 245,375 |
Dividend Payable |
| 507,298 |
| 353 |
Income Tax Payable |
| 403,453 |
| 420,925 |
|
|
|
|
|
TOTAL EQUITY AND LIABILITIES |
| 36,360,711 |
| 34,084,133 |
Beximco Pharmaceuticals Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the half year ended 31 December 2017
|
|
|
|
|
| Taka '000 | |
|
| Half Year ended 31 December 2017 |
| Half Year ended 31 December 2016 | 2nd Quarter (October-December 2017) | 2nd Quarter (October-December 2016) | |
|
|
|
|
|
|
| |
Net Sales Revenue |
| 8,638,539 |
| 7,630,591 | 4,359,864 | 3,864,993 | |
Cost of Goods Sold |
| (4,650,767) |
| (4,079,562) | (2,346,282) | (2,045,507) | |
|
|
|
|
|
|
| |
Gross Profit |
| 3,987,772 |
| 3,551,029 | 2,013,582 | 1,819,486 | |
|
|
|
|
|
|
| |
Operating Expenses |
| (1,996,013) |
| (1,785,365) | (980,237) | (917,401) | |
Administrative Expenses |
| (291,663) |
| (268,905) | (148,152) | (138,316) | |
Selling, Marketing and Distribution Expenses |
| (1,704,350) |
| (1,516,460) | (832,085) | (779,085) | |
|
|
|
|
|
|
| |
Profit from Operations |
| 1,991,759 |
| 1,765,664 | 1,033,345 | 902,085 | |
|
|
|
|
|
|
| |
Other Income |
| 28,809 |
| 97,394 | 6,398 | 53,020 | |
Finance Cost |
| (205,877) |
| (325,789) | (99,707) | (163,022) | |
Profit Before Contribution to WPPF & Welfare Funds |
| 1,814,691 |
| 1,537,269 | 940,036 | 792,083 | |
|
|
|
|
|
|
| |
Contribution to WPPF & Welfare Funds |
| (86,414) |
| (73,203) | (44,764) | (37,718) | |
|
|
|
|
|
|
| |
Profit Before Tax |
| 1,728,277 |
| 1,464,066 | 895,272 | 754,365 | |
|
|
|
|
|
|
| |
Income Tax Expenses |
| (410,859) |
| (351,125) | (222,350) | (156,374) | |
Current Tax |
| (416,443) |
| (335,234) | (213,806) | (170,235) | |
Deferred Tax |
| 5,584 |
| (15,891) | (8,544) | 13,861 | |
|
|
|
|
|
|
| |
Profit After Tax |
| 1,317,418 |
| 1,112,941 | 672,922 | 597,991 | |
Other Comprehensive Income-Unrealised Gain/(Loss) |
| (103) |
| 781 | 267 | 874 | |
|
|
|
|
|
|
| |
Total Comprehensive Income |
| 1,317,315 |
| 1,113,722 | 673,189 | 598,865 | |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
Earnings Per Share (EPS) / Adjusted EPS | Tk. | 3.25 |
| 2.74 | 1.66 | 1.47 | |
Number of Shares used to compute EPS | Nos. | 405,556,445 |
| 405,556,445 | 405,556,445 | 405,556,445 | |
Beximco Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the half year ended 31 December 2017
As at 31 December 2017 | Taka '000 | |||||||||||
| Share Capital | Share Premium | Excess of Issue Price over Face Value of GDRs | Capital Reserve on Merger | Revaluation Surplus | Un-realised Gain / (Loss) | Retained Earnings | Total | ||||
Balance as on 1 July 2017 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,190,204 | 3,875 | 12,568,720 | 25,072,426 | ||||
Total Comprehensive Income for the period: |
|
|
|
|
|
|
|
| ||||
Profit for the Period | - | - | - | - | - | - | 1,317,418 | 1,317,418 | ||||
Other Comprehensive Income / (Loss) | - | - | - | - | - | (103) | - | (103) | ||||
12.5 % Cash Dividend for 2016-2017 (July 2016 to June 2017) | - | - | - | - | - | - | (506,945) | (506,945) | ||||
Adjustment for Depreciation on Revalued Assets | - | - | - | - | (5,191) | - | 5,191 | - | ||||
Adjustment for Deferred Tax on Revalued Assets | - | - | - | - | (21,841) | - | - | (21,841) | ||||
Balance as on 31 December 2017 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,163,172 | 3,772 | 13,384,384 | 25,860,955 | ||||
|
|
|
|
|
|
|
|
| ||||
Number of Shares on 31 December 2017 |
|
|
|
|
|
|
| 405,556,445 | ||||
Net Asset Value (NAV) Per Share on 31 December 2017 |
|
|
|
|
|
| Tk. | 63.77 | ||||
As at 31 December 2016 | Taka '000 | |||||||||||
| Share Capital | Share Premium | Excess of Issue Price over Face Value of GDRs | Capital Reserve on Merger | Revaluation Surplus | Un-realised Gain / (Loss) | Retained Earnings | Total | ||||
Balance as on 1 July 2016 | 3,862,442 | 5,269,475 | 1,689,637 | 294,951 | 1,225,100 | 1,295 | 10,716,512 | 23,059,412 | ||||
Total Comprehensive Income for the period: |
|
|
|
|
|
|
|
| ||||
Profit for the Period | - | - | - | - | - | - | 1,112,941 | 1,112,941 | ||||
Other Comprehensive Income / (Loss) | - | - | - | - | - | 781 | - | 781 | ||||
5% Final Cash Dividend (January 2015 to June 2016) | - | - | - | - | - | - | (193,122) | (193,122) | ||||
5% Stock Dividend (January 2015 to June 2016) | 193,122 | - | - | - | - | - | (193,122) | - | ||||
Adjustment for Depreciation on Revalued Assets | - | - | - | - | (4,884) | - | 4,884 | - | ||||
Adjustment for Deferred Tax on Revalued Assets | - | - | - | - | (24,857) | - | - | (24,857) | ||||
Balance as on 31 December 2016 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,195,359 | 2,076 | 11,448,093 | 23,955,155 | ||||
|
|
|
|
|
|
|
|
| ||||
Number of Shares on 31 December 2016 |
|
|
|
|
|
|
| 405,556,445 | ||||
Net Asset Value (NAV) Per Share on 31 December 2016 |
|
|
|
|
|
| Tk. | 59.07 | ||||
Beximco Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the half year ended 31 December 2017
|
|
|
| Taka '000 | |
|
| Half year ended 31 December 2017 |
| Half year ended 31 December 2016 | |
|
|
|
|
| |
Cash Flows from Operating Activities: |
|
|
|
| |
|
|
|
|
| |
Receipts from Customers and Others |
| 8,318,280 |
| 7,355,078 | |
Payments to Suppliers and Employees |
| (6,443,336) |
| (5,784,971) | |
Cash Generated from Operations |
| 1,874,944 |
| 1,570,107 | |
|
|
|
|
| |
Interest Paid |
| (205,877) |
| (325,789) | |
Interest Received |
| 40,194 |
| 85,602 | |
Income Tax Paid |
| (433,915) |
| (293,245) | |
Net Cash Generated from Operating Activities |
| 1,275,346 |
| 1,036,675
| |
|
|
|
|
| |
Cash Flows from Investing Activities: |
|
|
|
| |
|
|
|
|
| |
Acquisition of Property, Plant and Equipment |
| (2,091,062) |
| (922,622) | |
Intangible Assets |
| (64,282) |
| (31,033) | |
Disposal of Property, Plant and Equipment |
| 1,354 |
| 2,953 | |
Decrease in Short Term Investment |
| 560,027 |
| 127,027 | |
Net Cash Used in Investing Activities |
| (1,593,963) |
| (823,675) | |
|
|
|
|
| |
Cash Flows from Financing Activities: |
|
|
|
| |
|
|
|
|
| |
Net Increase/(Decrease) in Long Term Borrowings |
| 948,653 |
| (306,110) | |
Net Increase/(Decrease) in Short Term Borrowings |
| (527,804) - |
| 334,243 (142,798) | |
Dividend Paid |
|
| |||
Net Cash Generated from Financing Activities |
| 420,849 |
| (114,665) | |
Increase / (Decrease) in Cash and Cash Equivalents |
| 102,232 |
| 98,335 | |
Cash and Cash Equivalents at Beginning of Period |
| 275,028 |
| 221,121 | |
Cash and Cash Equivalents at End of Period |
| 377,260 |
| 319,456 | |
|
|
|
|
| |
|
|
|
|
| |
Net Operating Cash Flow Per Share | Tk. | 3.14 |
| 2.56 | |
Number of Shares used to compute Net Operating Cash Flow Per Share |
| 405,556,445 |
| 405,556,445 | |